Current Issue

Clinical/translational cancer immunotherapy

• Original research: MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers (6 September, 2024)

  Iñaki Eguren-Santamaria, Eva Fernández de Piérola, Gracián Camps, Paula Martín-Muñoz, María Campos, Doina Cuculescu, Inmaculada Aguilera-Buenosvinos, Inmaculada Rodríguez López, Rafael Salido-Vallejo, Raluca Alexandru, Carlos E De Andrea, Laura Álvarez-Gigli, Pedro Berraondo, Ignacio Melero, Miguel F Sanmamed
• Original research: Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models (5 September, 2024)

  Dan Mei, Ziyang Xue, Tianjing Zhang, Yining Yang, Lin Jin, Qianqian Yu, Jian Hong, Xianzheng Zhang, Jinru Ge, Li Xu, Han Wang, Ziwei Zhang, Yuchen Zhao, Yuanfang Zhai, Qianshan Tao, Zhimin Zhai, Qingsheng Li, Hongxia Li, Lingling Zhang
• Original research: Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma (5 September, 2024)

  Tanya Ramadoss, Matthew Nichols, Christian Palacios, Zeynep Eroglu, Joseph Markowitz, Lilit Karapetyan, Ahmad A Tarhini, Evan J Wuthrick, Vernon K Sondak, Nikhil I Khushalani, Kenneth Y Tsai, Andrew S Brohl
• Original research: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy (3 September, 2024)

  Yanyang Nan, Yu Bai, Xiaozhi Hu, Kaicheng Zhou, Tao Wu, An Zhu, Mengyang Li, Zihan Dou, Zhonglian Cao, Xumeng Zhang, Shuwen Xu, Yuanzhen Zhang, Jun Lin, Xian Zeng, Jiajun Fan, Xuyao Zhang, Xuebin Wang, Dianwen Ju